Equities

Kymera Therapeutics Inc

KYMR:NMQ

Kymera Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)50.95
  • Today's Change1.09 / 2.19%
  • Shares traded300.19k
  • 1 Year change+219.44%
  • Beta2.2106
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Kymera Therapeutics Inc grew revenues 67.84% from 46.83m to 78.59m while net income improved from a loss of 154.81m to a smaller loss of 146.96m.
Gross margin--
Net profit margin-191.26%
Operating margin-228.63%
Return on assets-21.10%
Return on equity-26.00%
Return on investment-22.98%
More ▼

Cash flow in USDView more

In 2023, Kymera Therapeutics Inc increased its cash reserves by 55.35%, or 41.25m. Cash Flow from Investing totalled 139.89m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 102.83m for operations while cash generated from financing totalled 4.19m.
Cash flow per share-2.31
Price/Cash flow per share--
Book value per share13.79
Tangible book value per share13.79
More ▼

Balance sheet in USDView more

Kymera Therapeutics Inc uses little debt in its capital structure as supported by a debt to capital ratio of 0.35%.
Current ratio8.55
Quick ratio--
Total debt/total equity0.0035
Total debt/total capital0.0035
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.